Healing Discoveries by Holmes, Judy
The goal of treating diabetes with 
an effective, noninvasive oral 
delivery of insulin may one day 
be achieved through the use of a 
812-insulin system. 
Healing 
Discoveries 
Chemistry professor Robert Doyle leads 
a team of student researchers to new territories 
in the fights against diabetes and ovarian cancer 
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In his chemistry lab, Professor 
Robert Doyle explores 
ways to at tach drugs and 
other therapeutic agents to 
B-complex vitamins. 
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In less than two years since arriving at Syracuse University, ROB-
ERT DOYLE has guided his TEAM OF YOUNG RESEARCHERS on a 
journey of discovery, resulting in groundbreaking research that may 
lead to new treatments for DIABETES and OVARIAN CANCER. 
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For Doyle, a chemistry professor in the College of Arts and Sciences, 
discovery and innovation boil down to asking a simple question. "Some-
times a question arises in the literature, and you realize that you would 
like to be the first to answer it," Doyle says. " It 's even better if no one 
else is trying to answer the question the way you are ." 
In fact, it's those unanswered questions that Doyle finds most in-
triguing. That may be the reason his lab is one of only a handful of uni-
versity-based research labs worldwide that is exploring new ways to 
diagnose and treat diseases by attaching drugs and other therapeutic 
agents to B-complex vitamins, such as B12. Doyle's research team-
composed of 12 graduate and undergraduate students-discovered a 
way to administer insulin orally by coaxing vitamin B12 to give insulin a 
ride through the digestive system. His team is also making significant 
progress in attaching vitamin B9 (folic acid) to agents that can identify 
and kill drug-resistant ovarian cancer cells. The work may someday en-
able doctors to detect ovarian cancer at earlier stages than currently 
possible and to treat tumors more effectively with fewer side effects. 
Folic acid and B12 are essential ingredients in the cellular produc-
tion of deoxyribonucleic acid (DNA), which governs all cell processes. 
Because B vitamins are essential to cell survival , researchers believe 
the vitamins can be used to transport drugs and other therapeutic 
agents directly into cells before the active pharmaceutical agents are 
destroyed in the digestive system or excreted by the kidneys. 
It's an exploration that Doyle has immersed himself in for the past 
several years. A native of Ireland, Doyle earned a Ph.D in chemistry in 
2002 at Trinity College in Dublin and spent the next year as a postdoc-
Doctoral student Nerissa 
Villegas (above) focuses her 
research on developing a new 
method for detecting ovarian 
cancer cells at an early stage. 
On facing page, Professor 
Robert Doyle and doctoral 
student Amanda Petrus are 
part of a team that created a 
method for binding insulin (red) 
to vitamin B12 (yellow). 
The molecular image represents 
the B12-insulin conjugate bound 
to a B12 uptake protein . 
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toral fellow at Australian National University. In 2003, he joined 
the research team of Professor Ann Valentine at Yale University 
and was appointed a Rudolph Anderson Foundation Postdoctoral 
Fellow in 2004, allowing him to work on metallocylase enzymes 
and iron transport proteins. He was recruited by 
Syracuse University because of his expertise and 
interest in pursuing these new areas of research. 
"Often the trick is to make drugs that are not de-
stroyed before they reach their target," Doyle says. 
"Human cells can only get vitamins from the food 
we eat; therefore, vitamins tend to get a special 
pass through the digestive system, so they can be 
absorbed by the cells." 
JJ We asked ourselves, 
'Would B12 deliver 
insulin Orally?"' -ROBERTDOYLE 
New Way to Take Insulin 
More than 100 million people worldwide are afflicted by diabetes, 
a disease that inhibits the body's ability to effectively use glucose, 
which provides energy for all life processes. One form of diabetes 
is caused by the destruction of cells in the pancreas that produce 
the hormone insulin . The body uses insulin to transport glucose 
into cells, where it is used for energy or stored. This form of dia-
betes, known as insulin-dependent diabetes, requires patients to 
inject insulin into their bodies at least once a day. 
In the past no one had been completely successful at finding 
a way for insulin to be effective when taken orally. The problem 
was twofold: Researchers had to find a mechanism that would 
both prevent insulin from being destroyed in the digestive system 
and enable it to be absorbed from the digestive system into the 
bloodstream, where it could then interact with its receptor. Vita-
min B12 proved to be the answer to both problems. Because B12 is 
so critical to life processes, it passes through the digestive system 
unharmed and enters the bloodstream through specialized cells in 
the small intestine. Doyle's team, led by doctoral student Amanda 
Petrus, decided to investigate how insulin could hitch a ride with 
B12 as it travels through the digestive system and into the blood-
stream. "We asked ourselves, 'Would B12 deliver insulin orally?"' 
Doyle says. "It turns out that it could, but we didn't know that at 
the time. However, we could have told you a million reasons why 
it wouldn't work." 
The first step was to examine previous research to determine 
what had already been done to answer the question. There wasn't 
a lot to go on, but earlier studies had demonstrated it was possible. 
The key was to attach the agents so the body would still recognize 
the new compound as B12. "In some ways, you are standing on the 
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11 The chemistry to make the B9-PEG compound 
Doctoral student Anthony 
Vortherms leads the first 
university-based research 
team in the country to 
attach the cancer-killing 
drug AZT to a 89-polymer 
compound. 
is relatively simple and well worked out. But no one 
had used AZT before to target ovarian cancer cells." 
increase its effectiveness. The team is also col-
laborating with Robert Smith of the N.C. Brown 
Center for Ultrastructure Studies at the SUNY 
College of Environmental Science and Forestry, 
on a series of specialized experiments that use a 
technique called gold-based electron microsco-
py to take pictures of insulin binding to glucose. 
-ANTHONY VORTHERMS 
shoulders of giants," Petrus says. "You look at what others have 
done and pull out pieces and processes that might work for you." 
Petrus spent almost a year combining those bits and pieces 
with processes she developed to create a method for successfully 
binding insulin to B12. One particularly difficult task was finding a 
way to isolate the individual insulin molecules. "Insulin molecules 
like to hang out with each other," Petrus says. "I found a way to 
prevent them from sticking together. Down the road, someone 
might apply the process I developed to his or her project." 
Once the oral insulin compound was successfully created, the 
Doyle group collaborated with Timothy Fairchild, an exercise sci-
ence professor in the School of Education, to determine if the 
compound was effective in lowering blood glucose in diabetic 
rats. Fairchild, who met Doyle when they both arrived at SU in 
fall 2005, has been investigating the effect of exercise on blood 
sugar (glucose) levels. Researchers in his lab also are studying 
the effect of high-fructose corn syrup on blood sugar and insulin 
concentrations in the bloodstream. In short, Fairchild's research 
involves looking at blood sugar and insulin on a human scale, 
whereas Doyle's research examines the same substances at a cel-
lular level-a perfect match from the researchers' perspective. 
Fairchild helped Petrus test her oral insulin compound in his 
laboratory. The test results were impressive from both a research 
perspective and for their broader implications. There is much 
work to do before researchers will know if Petrus's oral insulin 
compound will be effective for humans. However, the early re-
sults, published in the peer-reviewed journal ChemMedChem in 
December 2007, look promising. 
Doyle's research team will continue to refine the compound to 
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"We've proved you can use B12 to deliver insulin orally," Doyle 
says. "We know it works because we lowered blood glucose lev-
els. Following the insulin-binding act on a cellular level to show 
that it works is just good, careful science." 
Search-and-Destroy Mission 
Each year, more than 25,000 women in the United States are 
diagnosed with ovarian cancer, the fifth leading cause of cancer 
deaths in women. Ovarian cancer is difficult to detect and even 
more difficult to treat because the vast majority of cases are diag-
nosed after the cancer has spread beyond the ovaries. Currently, 
75 percent of women with ovarian cancer diagnosed in stage 
three or four die within five years of diagnosis. 
Two research teams in Doyle's lab hope to help turn the tide in 
the fight against ovarian cancer by finding ways to send vitamin B9 
(folic acid), tethered to some unique hitchhikers, on a mission to 
seek out and destroy ovarian cancer cells. While all cells need B9 to 
survive, cancer cells need particularly large amounts of the vitamin 
because they grow and reproduce at such rapid rates. To take in 
large amounts of B9, some types of cancer cells, including ovarian 
ones, continue to rely on a system present in normal cells only dur-
ing fetal development and early infancy. Doyle's research teams are 
using this system, called the B9 (or folate) receptor system, as a 
targeted entry route into the cancer cells. Because this B9 receptor 
doorway is not present in normal cells, researchers hope it can be 
used to deliver drugs and other agents directly to the cancer cells 
without harming normal tissue. "In essence, what we want to do 
is tell an imaging agent or drug to only find and/or kill the cancer 
cells," Doyle says. "If successful, we will be able to detect ovarian 
cancer at an earlier stage and then kill it more effectively using low-
er dosages of a drug or radiation and with fewer side effects." 
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The problem both research teams had to first overcome was 
finding a way to prevent the B9 "Trojan horse" from being excreted 
by the kidneys before it gets through the back door. B9 is a water-
soluble vitamin. Excess quantities of the vitamin found circulating 
in the bloodstream are easily absorbed and excreted by the kid-
neys. To solve this problem, the teams explored previous research 
and developed a process for attaching B9 to a polyethylene glycol 
(PEG) polymer. The polymer enlarges the B9 molecule, making it 
harder for the kidneys to excrete and allowing larger quantities of 
the B9 Trojan horse to get past the kidneys and reach the intended 
target. The imaging agents and drugs are attached to the B9-PEG 
unit so they, too, can get by the kidneys. 
Killing Cancer Cells 
Using this B9-PEG system, a group led by doctoral student Antho-
ny Vortherms was the first university-based research team in the 
country to attach the cancer-killing drug AZT to the compound . 
They then successfully targeted and killed drug-resistant ovar-
ian cancer cells grown in Doyle's lab. Although AZT is currently 
used to treat people infected with the human immunodeficiency 
virus (H IV), it was originally designed as an anticancer agent, but 
proved too toxic. Vortherms's research was published as the lead 
article in the January 2008 issue of Nucleosides, Nucleotides, and 
Nucleic Acids, a peer-reviewed journal. "The chemistry to make 
the B9-PEG compound is relatively simple and well worked out," 
Vortherms says. "But no one had used AZT before to target ovar-
ian cancer cells." 
Vortherms continues to refine and test his compound on ovar-
ian cancer cells. He and Doyle will collaborate with Dawn Post, a 
neurosurgery professor at SUNY Upstate Medical University's In-
stitute for Human Performance, to determine the compound's po-
tential for further development as a drug to treat ovarian cancer. 
Illuminating Cancer Cells 
Another research team in Doyle's lab, led by doctoral student 
Nerissa Villegas, is working to develop a new method of detecting 
ovarian cancer cells by attaching the metals rhenium and techne-
tium to the B9-PEG compound. When B9 and its metal hitchhik-
ers enter cancer cells, the cells light up when scanned 
by an imaging device. Different isotopes or forms of the 
metals also have the potential to kill the cancer cells. 
"Currently, ovarian cancer is virtually undetectable in 
the early stages," Doyle says. "Our work is showing a lot 
of promise in this area." 
Villegas's team collaborates on the rhenium research 
with chemistry professor and department chair Jon Zu-
bieta, and on the technetium work with researchers at 
McMaster University in Hamilton, Ontario, which has 
facilities for handling radioactive metals. A third promis-
ing metal, gallium, presented especially difficult control 
problems, which Villegas had to solve before it could 
be tested in combination with the B9-PEG compound. 
That research, which took two years, was published in 
Polyhedron (December 2006), a peer-reviewed journal. 
"In that paper, we actually described the structure of 
the cage that traps the gallium and makes it behave," 
Doyle says. "Gallium 67 [a radioactive form that emits 
gamma rays] is potentially a potent killer of ovarian 
cancer cells. The trick is being able to handle the gallium and to 
show that it goes where it is supposed to go." 
During the past year, Villegas has been building on her earlier 
research to develop a method to attach gallium to the lab's B9-
PEG compound to target ovarian cancer cells. The hope was that 
the compound would kill the cells. Instead, the compound suc-
cessfully targeted the cancer cells, but did not kill them. This work, 
however, showed that these systems have great potential for use 
as non-toxic, controllable, imaging agents to detect ovarian can-
cer cells. The results of Villegas's research will be published in an 
upcoming issue of Drug Targets Insight, a peer-reviewed journal. 
"Even though we didn't get the expected results, we have contrib-
uted to the field," Villegas says. "The good news is we proved we 
could use gallium to target cancer cells. This work shows when 
you are careful and follow through on your idea that sometimes 
unexpected-but exciting-results can occur." 
The struggle to find new ways to fight ovarian cancer is both a 
personal and a professional quest for Villegas, whose mother died 
of the disease in 2005, two days before Villegas was accepted into 
SU's Ph.D. program. "My goal when I came here was to do cancer 
research," she says. "When I learned about Professor Doyle's re-
search, I decided to switch from organic chemistry to inorganic, 
so I could work on ways to target ovarian cancer." Villegas says 
working with rhenium and technetium is "a breeze" compared to 
gallium, but she is not giving up on gallium. "Not many labs work 
with gallium because it is so difficult," she says. "The early suc-
cesses with the rhenium and technetium experiments are giving 
me an emotional break from gallium." 
As work continues on the B9 and B12 avenues of research, 
Doyle is always looking for that next unanswered question. He 
plans to expand his research to include an exploration of vitamin 
Bl (thiamine) to see how it might be used as a delivery vehicle. 
"Bl is an interesting system," he says. "We're going to see where 
it takes us." And that, Doyle says, is the essence of fundamental 
research. "You want to do research that will have an impact 20 
years from now," he says. "What we learn through fundamental 
research stays around for a long time and has an impact on the 
future of science and discovery." 
Amy Rabideau '09 is among the undergraduates who work on 
research teams in Professor Robert Doyle's lab. 
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